India’s First Episkin-L’Oreal Innovation Challenge To Conclude With Grand Finale In Bengaluru
Mumbai, Maharashtra Nov 24, 2025 (Issuewire.com) - Krishgen Biosystems Private Limited, India, in collaboration with EPISKIN SA, France (LOreal Research & Innovation; world leader's in tissue engineering for in vitro human skin and epithelial models) will host the Grand Finale of the BioReImagine Innovation Challenge 2025 on Thursday, November 27, 2025 - and we invite members to attend for an evening of innovation data, networking and keynote talks.
The event marks the culmination of Indias first national-level innovation challenge promoting ethical, non-animal testing research using EPISKINs reconstructed human tissue models. The top three finalists from across India will present their proof-of-concept projects to an expert jury comprising scientists, industry leaders, and regulatory professionals. Keynote sessions by senior ADMET and life-science experts will highlight how reconstructed human tissue technologies are transforming predictive toxicology, safety assessment, and regulatory science.
BioReimagine 2025 is a step toward Indias scientific future - where innovation and ethics go hand in hand to offer innovation in skin models in translational research for drug discovery, wound management and cosmetic applications, said Dr Kalpesh Jain, Director, Krishgen Biosystems Private Limited.
Date: November 27, 2025 | Time: 3:00 PM 7:00 PM | Venue: NIMHANS Convention Centre, Bengaluru
Know More At:
Media Contact
More On Toptelecast ::
- Neti group state bank - 2025 press release
- A Lifetime of Study Unveils Biblical Truths on the End Times
- Uplifting Messages of Faith and Real-Life Wisdom
- Printify Explains How to Start a Hoodie Business in 2026
- Experience the Future of Wellness at Geneva Primary Care - Med Spa with Shivani Jerath, MD
KRISHGEN BIOSYSTEMS PRIVATE LIMITED
912249198700
Unit Nos 318 319 Shah and Nahar Off Dr E Moses Road Worli
Source :KRISHGEN BIOSYSTEMS PRIVATE LIMITED
This article was originally published by IssueWire. Read the original article here.